Start-Up Quarterly Statistics, Q4 2008
This article was originally published in Start Up
Highlights from the Q4 2008 review of start-up dealmaking: Fundraising in the biopharma, med-device, and in vitro diagnostics industries totaled $551 million, a 41% decrease from 3Q and just another indication of the tough economic times. Of the three acquisitions done this quarter--two in biopharma and one in devices--only one had a disclosed value. About one-third of the 19 biopharma alliances were in the cancer therapy area.
You may also be interested in...
Metabolic disorders is one of six focus areas targeted by Wyeth’s new discovery plan.
Cancer stem cells are a hot, promising new approach to treating cancer--one which may not only prevent cancer from spreading, but also help diagnose and even cure the disease. Start-ups are beginning to emerge, and so is investor interest.
OncoMed Pharmaceuticals' mission is to translate its founders' cancerous stem cell insights into novel medicines capable of eliminating the cancer stem cell and halting the spread of solid tumors. The company has identified about 50 proteins characteristic of cancer stem cells and has established a large library of antibodies capable of binding to them. It is also identifying small-molecule compounds that can halt these cancer stem cells.